Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.
Tulika Ranjan
No relevant relationships to disclose
Katherine B. Peters
No relevant relationships to disclose
Gordana Vlahovic
Consultant or Advisory Role - Genentech/Roche
Honoraria - Genentech/Roche
Lloyd M Alderson
No relevant relationships to disclose
James Emmett Herndon
No relevant relationships to disclose
Frances McSherry
No relevant relationships to disclose
Stevie Threatt
No relevant relationships to disclose
John Howard Sampson
No relevant relationships to disclose
Allan H. Friedman
No relevant relationships to disclose
Darell D. Bigner
No relevant relationships to disclose
Henry S. Friedman
Consultant or Advisory Role - Genentech/Roche
Honoraria - Genentech/Roche
Research Funding - Genentech/Roche
James J Vredenburgh
Consultant or Advisory Role - Genentech/Roche
Honoraria - Genentech/Roche
Annick Desjardins
Consultant or Advisory Role - Genentech/Roche
Research Funding - Genentech/Roche